PH12021550114A1 - T cell-antigen coupler with various construct optimizations - Google Patents

T cell-antigen coupler with various construct optimizations

Info

Publication number
PH12021550114A1
PH12021550114A1 PH12021550114A PH12021550114A PH12021550114A1 PH 12021550114 A1 PH12021550114 A1 PH 12021550114A1 PH 12021550114 A PH12021550114 A PH 12021550114A PH 12021550114 A PH12021550114 A PH 12021550114A PH 12021550114 A1 PH12021550114 A1 PH 12021550114A1
Authority
PH
Philippines
Prior art keywords
optimizations
cell
different
ucht1
antigen coupler
Prior art date
Application number
PH12021550114A
Inventor
Jonathan Lorne Bramson
Christopher W Helsen
Joanne Alicia Hammill
Kenneth Anthony Mwawasi
Original Assignee
Triumvira Immunologics Usa Inc
Univ Mcmaster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/442,274 external-priority patent/US10640562B2/en
Application filed by Triumvira Immunologics Usa Inc, Univ Mcmaster filed Critical Triumvira Immunologics Usa Inc
Publication of PH12021550114A1 publication Critical patent/PH12021550114A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
PH12021550114A 2018-07-17 2021-01-15 T cell-antigen coupler with various construct optimizations PH12021550114A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862699173P 2018-07-17 2018-07-17
US201862703037P 2018-07-25 2018-07-25
US201862773120P 2018-11-29 2018-11-29
US201962826853P 2019-03-29 2019-03-29
US201962828879P 2019-04-03 2019-04-03
US201962839235P 2019-04-26 2019-04-26
US16/442,274 US10640562B2 (en) 2018-07-17 2019-06-14 T cell-antigen coupler with various construct optimizations
US201962874426P 2019-07-15 2019-07-15
PCT/US2019/042297 WO2020018727A1 (en) 2018-07-17 2019-07-17 T cell-antigen coupler with various construct optimizations

Publications (1)

Publication Number Publication Date
PH12021550114A1 true PH12021550114A1 (en) 2021-10-04

Family

ID=69163917

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550114A PH12021550114A1 (en) 2018-07-17 2021-01-15 T cell-antigen coupler with various construct optimizations

Country Status (12)

Country Link
EP (1) EP3823984A4 (en)
JP (1) JP7404279B2 (en)
KR (1) KR20210021593A (en)
CN (1) CN112689642A (en)
AU (1) AU2019307905A1 (en)
BR (1) BR112021000735A2 (en)
CA (1) CA3104887A1 (en)
IL (1) IL280049A (en)
MX (1) MX2021000541A (en)
PH (1) PH12021550114A1 (en)
SG (1) SG11202100307WA (en)
WO (1) WO2020018727A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435453B2 (en) 2014-02-07 2019-10-08 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
EP3694997A4 (en) 2017-10-12 2021-06-30 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
EP4326889A2 (en) 2021-04-21 2024-02-28 Conagen Inc. Biosynthetic production of delta-lactones using cytochrome p450 hydroxylase enzymes or mutants thereof
WO2022256449A1 (en) 2021-06-01 2022-12-08 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2794658T (en) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecific antibody molecule
SG11201408787PA (en) * 2012-07-13 2015-01-29 Univ Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
US10435453B2 (en) 2014-02-07 2019-10-08 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
MX2017012939A (en) * 2015-04-08 2018-05-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell.
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3472318B1 (en) * 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2018027155A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN108250302A (en) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 A kind of multifunctional protein

Also Published As

Publication number Publication date
MX2021000541A (en) 2021-08-16
EP3823984A4 (en) 2022-04-06
WO2020018727A1 (en) 2020-01-23
CN112689642A (en) 2021-04-20
KR20210021593A (en) 2021-02-26
BR112021000735A2 (en) 2021-07-13
EP3823984A1 (en) 2021-05-26
AU2019307905A1 (en) 2021-03-04
JP2021530971A (en) 2021-11-18
JP7404279B2 (en) 2023-12-25
CA3104887A1 (en) 2020-01-23
SG11202100307WA (en) 2021-02-25
IL280049A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
PH12021550114A1 (en) T cell-antigen coupler with various construct optimizations
EP4249068A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
IL265541B1 (en) Bispecific antibodies and compositions comprising thereof for treating cancer
MX2019003350A (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases.
JP2017504578A5 (en)
MX2022001273A (en) Heterotandem bicyclic peptide complex.
JP2015502373A5 (en)
MX2016015389A (en) Antibodies binding to human and cynomolgus cd3 epsilon.
SG195077A1 (en) Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
JP2017504577A5 (en)
WO2019005640A3 (en) Multi-specific antibodies and methods of making and using thereof
MX2020002880A (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1).
RU2013157040A (en) POLYVALENT ANTIGEN-BINDING FV-MOLECULE
JOP20200234A1 (en) Modified a1-a2 domains of non-natural nkg2d ligands that bind non-natural nkg2d receptors
JP2024023228A5 (en)
EA201691782A1 (en) ANTIBODIES SPECIFIC TO THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1, AND THEIR APPLICATION
RU2018137419A (en) BINDING TO CD38 AND PD-L1 MOLECULES
EA201691779A1 (en) ANTIBODIES SPECIFIC TO THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1, AND THEIR APPLICATION
MX2023010499A (en) Heterodimeric antibodies that bind cd3 and cldn6.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2023009022A (en) Multispecific antibodies having specificity for ror1 and cd3.
MX2021009275A (en) Cd3-specific binding molecules.
ZA202107047B (en) Heterodimeric antibodies that bind enpp3 and cd3
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof